Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Promising combination of ixazomib, lenalidomide & dex in high-risk smoldering myeloma

Mark Bustoros • 1 Dec 2018
ASH 2018
Multiple Myeloma Dexamethasone Ixazomib Lenalidomide

Mark Bustoros, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the Phase II trial (NCT02916771) assessing the PFS and response rate following the combination of ixazomib, lenalidomide and dexamethasone for the treatment of high-risk smoldering multiple myeloma (SMM). Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Busteros discusses the promising efficacy, tolerability and response rate of this combination, before revealing his future expectations for this treatment.

More from Mark Bustoros

3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
1:11
Advances that have been made in the molecular characterization of multiple myeloma
Mark Bustoros • 27 Sep 2023
1:50
Molecular characteristics of extramedullary myeloma
Mark Bustoros • 27 Sep 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals